# Oral vs Intravenous Diltiazem for Rapid Atrial Fibrillation/Flutter Trial

> **NCT03472495** · PHASE4 · COMPLETED · sponsor: **Virginia Commonwealth University** · enrollment: 19 (actual)

## Conditions studied

- Atrial Fibrillation and Flutter

## Interventions

- **DRUG:** Diltiazem Oral Product
- **DRUG:** Diltiazem Injectable Product

## Key facts

- **NCT ID:** NCT03472495
- **Lead sponsor:** Virginia Commonwealth University
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-06-01
- **Primary completion:** 2021-03-21
- **Final completion:** 2021-03-21
- **Target enrollment:** 19 (ACTUAL)
- **Last updated:** 2023-03-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03472495

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03472495, "Oral vs Intravenous Diltiazem for Rapid Atrial Fibrillation/Flutter Trial". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT03472495. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*